17-July-2019: The global neuroendocrine
tumor (NET) treatment market size is expected to reach
USD 3.33 billion by 2025, according to a new report by Grand View Research,
Inc. The market is estimated to register a CGAR of 10.4% during the forecast
period. The increasing pervasiveness of carcinoid tumors is expected to drive the
market over the forecast period. Heavy investment in clinical trials by various
pharmaceutical companies to develop novel products is another factor propelling
the market development.
For instance, Novartis
AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen
Pharma. Moreover, technological advancements in therapies to treat
neuroendocrine tumors are anticipated to fuel the market growth over the coming
years. Some of these include PET imaging with Ga labeled Somatostatin, targeted
drug therapies, and tyrosine kinase therapies. For instance, Lutathera by
Novartis AG received FDA approval for the first ever radionucleotide therapy.
In
depth research report on Neuroendocrine Tumor Treatment Market
Further key findings from the study suggest:
·
Somatostatin analogs segment accounted for the largest
revenue share of more than 60% in 2017 owing to its cost-effective and safe
therapy procedure
·
The pancreas segment is expected to exhibit the highest
growth in the neuroendocrine tumor treatment market over the forecast period
·
Clinics segment is expected to register the highest CAGR of
10.9% over the estimated period due to increasing patient preference for
clinics over other healthcare settings
·
North America held the largest share of the global
neuroendocrine tumor treatment market in 2017 mainly due to favorable
government insurance policies
·
Some of the key companies in the global market are Pfizer,
Inc.; Novartis AG; Ipsen Pharma; and Boehringer Ingelheim International GmbH.
Major companies focus more on R&D to develop novel therapeutics for NETs.
Grand View Research
has segmented the global neuroendocrine tumor treatment market on the basis of
product, site, end use, and region:
NET Treatment Product Outlook (Revenue, USD Million, 2014 -
2025)
·
Somatostatin Analogs (SSAs)
·
Targeted Therapy
·
Others
NET Treatment Site Outlook (Revenue, USD Million, 2014 -
2025)
·
Lungs
·
Pancreas
·
Colon
·
Small Intestine
·
Others
NET Treatment End-use Outlook (Revenue, USD Million, 2014 -
2025)
·
Hospitals
·
Clinics
·
Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment